Abstract
Alzheimer's Disease (AD) is an irreversible, incurable, progressive neurodegenerative illness, where dementia symptoms gradually worsen over a number of years. The research of validated biomarkers for Alzheimer's disease is essential to improve diagnosis and accelerate the development of new therapies.
Biochemical markers including neuroimaging could facilitate diagnosis, predict AD progression from a pre-AD state of mild cognitive impairment (MCI), and be used to detect efficacies of disease-modifying therapies. Established biomarkers of AD from cerebrospinal fluid (CSF) and neuroimaging are highly accurate, but barriers to clinical implementation exist.
The focus on blood-based AD biomarkers has grown exponentially during the past decades. An ideal diagnostic test for AD should be non-invasive and easily applicable.
Clinical cost-effectiveness also needs to be established.